Cancer Research The Future of Cancer Research: Science and Patient Impact Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thomson, S.
Right arrow Articles by Haley, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomson, S.
Right arrow Articles by Haley, J. D.
[Cancer Research 65, 9455-9462, October 15, 2005]
© 2005 American Association for Cancer Research

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non–Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition

Stuart Thomson1, Elizabeth Buck1, Filippo Petti1, Graeme Griffin2, Eric Brown2, Nishal Ramnarine1, Kenneth K. Iwata1, Neil Gibson2 and John D. Haley1

Departments of 1 Translational Research and 2 Oncology Research, OSI Pharmaceuticals, Inc., Farmingdale, New York

Requests for reprints: John D. Haley, Department of Translational Research, OSI Pharmaceuticals, Inc., 1 Bioscience Park Drive, Farmingdale, NY 11735. Phone: 631-962-0709; Fax: 631-845-5671; E-mail: jhaley{at}osip.com.

Treatment of second- and third-line patients with non–small-cell lung carcinoma (NSCLC) with the epidermal growth factor receptor (EGFR) kinase inhibitor erlotinib significantly increased survival relative to placebo. Whereas patient tumors with EGFR mutations have shown responses to EGFR inhibitors, an exclusive role for mutations in patient survival benefit from EGFR inhibition is unclear. Here we show that wild-type EGFR–containing human NSCLC lines grown both in culture and as xenografts show a range of sensitivities to EGFR inhibition dependent on the degree to which they have undergone an epithelial to mesenchymal transition (EMT). NSCLC lines which express the epithelial cell junction protein E-cadherin showed greater sensitivity to EGFR inhibition in vitro and in xenografts. In contrast, NSCLC lines having undergone EMT, expressing vimentin and/or fibronectin, were insensitive to the growth inhibitory effects of EGFR kinase inhibition in vitro and in xenografts. The differential sensitivity of NSCLC cells with epithelial or mesenchymal phenotypes to EGFR inhibition did not correlate with cell cycle status in vitro or with xenograft growth rates in vivo, or with total EGFR protein levels. Cells sensitive to EGFR inhibition, with an epithelial cell phenotype, did exhibit increased phosphorylation of EGFR and ErbB3 and a marked increase in total ErbB3. The loss of E-cadherin and deregulation of ß-catenin associated with EMT have been shown to correlate with poor prognosis in multiple solid tumor types. These data suggest that EMT may be a general biological switch rendering non–small cell lung tumors sensitive or insensitive to EGFR inhibition.




This article has been cited by other articles:


Home page
 Arch NeurolHome page
H. Colman and K. Aldape
Molecular Predictors in Glioblastoma: Toward Personalized Therapy
Arch Neurol, July 1, 2008; 65(7): 877 - 883.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. N. Fleming, M. Hogben, S. Frame, S. J. McClue, and S. R. Green
Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents
Clin. Cancer Res., July 1, 2008; 14(13): 4326 - 4335.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. A. Hassig, K. T. Symons, X. Guo, P.-M. Nguyen, T. Annable, P. L. Wash, J. E. Payne, D. A. Jenkins, C. Bonnefous, C. Trotter, et al.
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
Mol. Cancer Ther., May 1, 2008; 7(5): 1054 - 1065.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. C. Fuchs, T. Fujii, J. D. Dorfman, J. M. Goodwin, A. X. Zhu, M. Lanuti, and K. K. Tanabe
Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells
Cancer Res., April 1, 2008; 68(7): 2391 - 2399.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Tanaka, A. Munshi, C. Brooks, J. Liu, M. L. Hobbs, and R. E. Meyn
Gefitinib Radiosensitizes Non-Small Cell Lung Cancer Cells by Suppressing Cellular DNA Repair Capacity
Clin. Cancer Res., February 15, 2008; 14(4): 1266 - 1273.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y.-M. Hsu, Y.-F. Chen, C.-Y. Chou, M.-J. Tang, J. H. Chen, R. J. Wilkins, J. C. Ellory, and M.-R. Shen
KCl Cotransporter-3 Down-regulates E-Cadherin/{beta}-Catenin Complex to Promote Epithelial-Mesenchymal Transition
Cancer Res., November 15, 2007; 67(22): 11064 - 11073.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H.-W. Lo, S.-C. Hsu, W. Xia, X. Cao, J.-Y. Shih, Y. Wei, J. L. Abbruzzese, G. N. Hortobagyi, and M.-C. Hung
Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression
Cancer Res., October 1, 2007; 67(19): 9066 - 9076.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Wang, C. Sloss, X. Zhang, S. W. Lee, and J. C. Cusack
Membrane-Bound Heparin-Binding Epidermal Growth Factor Like Growth Factor Regulates E-Cadherin Expression in Pancreatic Carcinoma Cells
Cancer Res., September 15, 2007; 67(18): 8486 - 8493.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Rosano, V. Di Castro, F. Spinella, G. Tortora, M. R. Nicotra, P. G. Natali, and A. Bagnato
Combined Targeting of Endothelin A Receptor and Epidermal Growth Factor Receptor in Ovarian Cancer Shows Enhanced Antitumor Activity
Cancer Res., July 1, 2007; 67(13): 6351 - 6359.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Yang, J. M. Amann, T. Kikuchi, R. Porta, M. Guix, A. Gonzalez, K.-H. Park, D. Billheimer, C. L. Arteaga, H.-H. Tai, et al.
Inhibition of Epidermal Growth Factor Receptor Signaling Elevates 15-Hydroxyprostaglandin Dehydrogenase in Non-Small-Cell Lung Cancer
Cancer Res., June 15, 2007; 67(12): 5587 - 5593.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Yamasaki, M. J. Johansen, D. Zhang, S. Krishnamurthy, E. Felix, C. Bartholomeusz, R. J. Aguilar, K. Kurisu, G. B. Mills, G. N. Hortobagyi, et al.
Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt
Cancer Res., June 15, 2007; 67(12): 5779 - 5788.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. A. Frederick, B. A. Helfrich, C. D. Coldren, D. Zheng, D. Chan, P. A. Bunn Jr., and D. Raben
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma
Mol. Cancer Ther., June 1, 2007; 6(6): 1683 - 1691.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Steiner, C. Joynes, R. Bassi, S. Wang, J. R. Tonra, Y. R. Hadari, and D. J. Hicklin
Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non-Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor
Clin. Cancer Res., March 1, 2007; 13(5): 1540 - 1551.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. Buck, A. Eyzaguirre, S. Barr, S. Thompson, R. Sennello, D. Young, K. K. Iwata, N. W. Gibson, P. Cagnoni, and J. D. Haley
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
Mol. Cancer Ther., February 1, 2007; 6(2): 532 - 541.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Shrader, M. S. Pino, G. Brown, P. Black, L. Adam, M. Bar-Eli, C. P.N. Dinney, and D. J. McConkey
Molecular correlates of gefitinib responsiveness in human bladder cancer cells
Mol. Cancer Ther., January 1, 2007; 6(1): 277 - 285.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Rosell, M. Taron, N. Reguart, D. Isla, and T. Moran
Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway
Clin. Cancer Res., December 15, 2006; 12(24): 7222 - 7231.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. Buck, A. Eyzaguirre, E. Brown, F. Petti, S. McCormack, J. D. Haley, K. K. Iwata, N. W. Gibson, and G. Griffin
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
Mol. Cancer Ther., November 1, 2006; 5(11): 2676 - 2684.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. D. Carey, A. J. Garton, M. S. Romero, J. Kahler, S. Thomson, S. Ross, F. Park, J. D. Haley, N. Gibson, and M. X. Sliwkowski
Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib
Cancer Res., August 15, 2006; 66(16): 8163 - 8171.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. H. Chung, J. S. Parker, K. Ely, J. Carter, Y. Yi, B. A. Murphy, K. K. Ang, A. K. El-Naggar, A. M. Zanation, A. J. Cmelak, et al.
Gene Expression Profiles Identify Epithelial-to-Mesenchymal Transition and Activation of Nuclear Factor-{kappa}B Signaling as Characteristics of a High-risk Head and Neck Squamous Cell Carcinoma
Cancer Res., August 15, 2006; 66(16): 8210 - 8218.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. L. Knutson, H. Lu, B. Stone, J. M. Reiman, M. D. Behrens, C. M. Prosperi, E. A. Gad, A. Smorlesi, and M. L. Disis
Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition
J. Immunol., August 1, 2006; 177(3): 1526 - 1533.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. Buck, A. Eyzaguirre, J. D. Haley, N. W. Gibson, P. Cagnoni, and K. K. Iwata
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
Mol. Cancer Ther., August 1, 2006; 5(8): 2051 - 2059.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
C. D. Coldren, B. A. Helfrich, S. E. Witta, M. Sugita, R. Lapadat, C. Zeng, A. Baron, W. A. Franklin, F. R. Hirsch, M. W. Geraci, et al.
Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non-Small Cell Lung Cancer Cell Lines
Mol. Cancer Res., August 1, 2006; 4(8): 521 - 528.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
V. Dasari, M. Gallup, H. Lemjabbar, I. Maltseva, and N. McNamara
Epithelial-Mesenchymal Transition in Lung Cancer: Is Tobacco the "Smoking Gun"?
Am. J. Respir. Cell Mol. Biol., July 1, 2006; 35(1): 3 - 9.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Jin, K. K. Iwata, A. Belldegrun, R. Figlin, A. Pantuck, Z.-F. Zhang, R. Lieberman, and J. Rao
Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model.
Mol. Cancer Ther., July 1, 2006; 5(7): 1754 - 1763.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. A. Bunn Jr., R. Dziadziuszko, M. Varella-Garcia, W. A. Franklin, S. E. Witta, K. Kelly, and F. R. Hirsch
Biological Markers for Non-Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy.
Clin. Cancer Res., June 15, 2006; 12(12): 3652 - 3656.
[Full Text] [PDF]

Home page
 JCOHome page
E. E.W. Cohen
Role of Epidermal Growth Factor Receptor Pathway-Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., June 10, 2006; 24(17): 2659 - 2665.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Kalyankrishna and J. R. Grandis
Epidermal Growth Factor Receptor Biology in Head and Neck Cancer
J. Clin. Oncol., June 10, 2006; 24(17): 2666 - 2672.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. L. Reckamp, K. Krysan, J. D. Morrow, G. L. Milne, R. A. Newman, C. Tucker, R. M. Elashoff, S. M. Dubinett, and R. A. Figlin
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Clin. Cancer Res., June 1, 2006; 12(11): 3381 - 3388.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Dohadwala, S.-C. Yang, J. Luo, S. Sharma, R. K. Batra, M. Huang, Y. Lin, L. Goodglick, K. Krysan, M. C. Fishbein, et al.
Cyclooxygenase-2-Dependent Regulation of E-Cadherin: Prostaglandin E2 Induces Transcriptional Repressors ZEB1 and Snail in Non-Small Cell Lung Cancer.
Cancer Res., May 15, 2006; 66(10): 5338 - 5345.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Biol.Home page
J. M. Lee, S. Dedhar, R. Kalluri, and E. W. Thompson
The epithelial-mesenchymal transition: new insights in signaling, development, and disease.
J. Cell Biol., March 27, 2006; 172(7): 973 - 981.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. M. Lippman and J. J. Lee
Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture.
Cancer Res., March 15, 2006; 66(6): 2893 - 2903.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.